The impact of pleural disease on the management of advanced ovarian cancer

Escayola, Cecilia; Ferron, Gwénaël; Romeo, Margarita; Torrent, Juan José; Querleu, Denis

doi:10.1016/j.ygyno.2015.05.003

Cited by 14 publications

(7 citation statements)

References 43 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This case illustrates the challenges related to the treatment of patients with advanced EOC and pleural disease. Despite being the most common metastatic site of stage IV EOC, the accuracy rate of pleural cytology for suspicious effusions remains low and management can be complex ( Escayola et al, 2015 ). In this case, the patient was initially given NACT, since stage IVB patients benefit from it and response to treatment is a good prognostic factor ( Tajik et al, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

Hyperthermic intraoperative thoracoabdominal chemotherapy for stage IVB epithelial ovarian carcinoma

Brind’Amour

Tremblay

Fortin

et al. 2020

Gynecologic Oncology Reports

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Hyperthermic intraoperative thoracoabdominal chemotherapy for stage IVB epithelial ovarian carcinoma

Brind’Amour

Tremblay

Fortin

et al. 2020

Gynecologic Oncology Reports

View full text Add to dashboard Cite

show abstract

“…Herein, VATS led to a change in stage of disease in 41% of patients. Both Escayola et al [35] and Di Guilmi et al [36] conclude that VATS may facilitate the selection of patients for PCS. Importantly, VATS should not be performed in patients with low likelihood of complete cytoreduction of tumor in abdomen and pelvis as these patients are candidates for NACT.…”

Section: Radiographic and Nuclear Imagingmentioning

confidence: 99%

“…Novel surgical techniques for diaphragmatic surgery (e.g., diaphragmatic peritoneal stripping and diaphragmatic full-thickness resection) have been developed, however the impact of these techniques on OS is still unclear [34]. A review by Escayola et al [35] recently concluded that it is currently unclear whether pleural involvement can reliably be assessed by CT scan and/or chest radiograph alone, and proposed that video-assisted thoracoscopy (VATS) could be a valuable tool in describing the extent of pleural disease. One of the key findings in a review by Di Guilmi et al [36] was that among patients with negative pleural cytology, 23.5% have pleural disease determined with VATS.…”

Section: Radiographic and Nuclear Imagingmentioning

confidence: 99%

Surgery for patients with newly diagnosed advanced ovarian cancer: which patient, when and extent?

Eggink

Koopmans²,

Nijman

2017

Current Opinion in Oncology

View full text Add to dashboard Cite

The past decade has seen a paradigm shift in the number of AvdEOC patients that are being treated with upfront neoadjuvant chemotherapy instead of PCS. However, although neoadjuvant chemotherapy may reduce morbidity at the time of interval cytoreductive surgery, no favorable impact on survival has been demonstrated and it may induce resistance to chemotherapy. Therefore, optimizing patient selection for PCS is crucial. Furthermore, surgical innovations in patients diagnosed with AvdEOC should focus on improving survival outcomes.

show abstract

“…Ovarian cancer is one of the most common malignant tumors in the female reproductive system and has the highest mortality among all gynecological tumors ( 1 , 2 ). Due to the absence of specific symptoms and detective tools, most ovarian cancer patients are diagnosed at advanced stages, and the 5-year survival rate remains at approximately 45% ( 3 , 4 ). Despite improvements in surgery and chemotherapy approaches, unfortunately, the majority of advanced patients eventually relapse and die of this disease.…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of PI3 and HLA-DOB as potential prognostic predicators for ovarian cancer

Li¹,

Li²,

Yang³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: The outcomes of ovarian cancer patients are very poor, therefore it is necessary to find prognostic biomarkers and explore the potential underlying molecular mechanisms of ovarian cancer.Methods: In this study, a gene expression microarray data set covering 562 ovarian serous cystadenocarcinomas and 12,042 genes was downloaded from The Cancer Genome Atlas (TCGA) database.For each candidate gene, samples were allocated into a "high group" or a "low group" according to the expression level. The overall survival (OS) rates were compared between the two groups. Then, a univariate analysis and a multivariate Cox proportional hazards test were carried out to examine the associations between genes and multiple clinicopathological parameters.Results: Among all candidate genes, PI3 (peptidase inhibitor 3, often called elafin) and HLA-DOB (major histocompatibility complex, class II, DO beta) were identified as hub genes. PI3 (P=7.99e-7) and HLA-DOB (P=7.52e-6) showed significant associations with OS, especially in patients with stage III or IV disease.Both PI3 (HR =1.84, P=3.77e-7) and HLA-DOB (HR =0.68, P=0.001134) were identified as independent predictors of ovarian cancer patients OS. In addition, IRF1 (interferon regulatory factor 1) (P=1.16e-15) and SPI1 (Spi-1 proto-oncogene) (P=2.03e-6) were identified as the most significant transcription factors. Conclusions:Our data indicate that PI3 and HLA-DOB are potential biomarkers that could be used to predict the prognosis of ovarian cancer patients, and may play important roles in ovarian cancer progression.Further experimental and clinical studies with larger sample sizes are needed to confirm these findings.

show abstract

The impact of pleural disease on the management of advanced ovarian cancer

Cited by 14 publications

References 43 publications

Hyperthermic intraoperative thoracoabdominal chemotherapy for stage IVB epithelial ovarian carcinoma

Hyperthermic intraoperative thoracoabdominal chemotherapy for stage IVB epithelial ovarian carcinoma

Surgery for patients with newly diagnosed advanced ovarian cancer: which patient, when and extent?

Clinical significance of PI3 and HLA-DOB as potential prognostic predicators for ovarian cancer

Contact Info

Product

Resources

About